Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - adalimumabum - injektionslösung in einer fertigspritze - lösung: adalimumabum 80 mg, natrii chloridum corresp. natrium 0.181 mg, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, früh diagnostizierte rheumatoide arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew) morbus crohn, plaque-psoriasis, colitis ulcerosa, polyartikuläre juvenile idiopathische arthritis, hidradenitis suppurativa, uveitis - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - adalimumabum - injektionslösung im fertigpen - lösung: adalimumabum 40 mg, natrii chloridum corresp. natrium 0.09 mg, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. - rheumatoide arthritis, früh diagnostizierte rheumatoide arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew) morbus crohn, plaque-psoriasis, colitis ulcerosa, polyartikuläre juvenile idiopathische arthritis, hidradenitis suppurativa, uveitis - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

fresenius kabi (schweiz) ag - adalimumabum - injektionslösung in fertigspritze - lösung: adalimumabum 40 mg, acidum citricum monohydricum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, mannitolum, polysorbatum 80, natrii chloridum, trinatrii citras dihydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn, dienen ulcerosa, plaque-psoriasis bei erwachsenen, hidradenitis suppurativa - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

fresenius kabi (schweiz) ag - adalimumabum - injektionslösung im fertigpen - lösung: adalimumabum 40 mg, acidum citricum monohydricum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, mannitolum, polysorbatum 80, natrii chloridum, trinatrii citras dihydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn, dienen ulcerosa, plaque-psoriasis bei erwachsenen, hidradenitis suppurativa - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

fresenius kabi (schweiz) ag - adalimumabum - injektionslösung in durchstechflasche - lösung: adalimumabum 40 mg, acidum citricum monohydricum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, mannitolum, polysorbatum 80, natrii chloridum, trinatrii citras dihydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - polyartikuläre juvenile idiopathische arthritis, morbus crohn bei kindern - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml. tela cum: alcohol isopropylicus. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - upadacitinibum - retardtablette - upadacitinibum 15 mg zu upadacitinibum hemihydricum, cellulosum microcristallinum, hypromellosum, mannitolum, säure-tartaricum, silica colloidalis anhydrica, magnesium stearas, poly(alkohol vinylicus), macrogolum 3350, talkum, e 171, e 172, für compresso dunst. - selektives immunsuppressivum - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunsuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Europäische Union - Deutsch - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.